They maintain low levels of IL1B during CAR T cell therapy to minimize IL-6- and IL-1-associated cytokine toxicity and neurotoxicity without impairing therapeutic efficacy in patients with hematological malignancy.50 This evidence concerns the gene IL6 and hematologic disorder.